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Abstract
Introduction: We aimed to enumerate the rate of pelvic recurrence 
following radical cystectomy at university-affiliated hospitals in 
Canada.
Methods: Canadian, university-affiliated hospitals were invited to 
participate. They were asked to identify the first 10 consecutive 
patients undergoing radical cystectomy starting January 1, 2005, 
who had urothelial carcinoma stages pT3/T4 N0-2 M0. The first 10 
consecutive cases starting January 1, 2005 who met these criteria 
were the patients submitted by that institution with information 
regarding tumour stage, age, number of nodes removed, and last 
known clinical status in regard to recurrence and patterns of failure.
Results: Of the 111 patients, 80% had pT3 and 20% pT4 disease, 
with 62% being node-negative, 14% pN1, and 27% pN2; 57% 
had 10 or more nodes removed. Cumulative incidence of pelvic 
relapse was 40% among the entire group
Conclusions: This review demonstrates a high rate of pelvic tumour 
recurrence following radical cystectomy for pT3/T4 urothelial cancer.
Introduction
The current gold standard management for locally advanced 
urothelial bladder cancer consists of neoadjuvant chemo-
therapy, followed by radical cystectomy with pelvic node 
dissection and neo-bladder reconstruction, as appropri-
ate.1,2 This combination addresses the loco-regional pelvic 
disease and the systemic micrometastatic tumour burden. 
Unfortunately, cure rates have remained static for over two 
decades, reflecting the lack of more effective systemic treat-
ment and a continuing problem with pelvic tumour eradica-
tion.3 We report the results of a Canadian academic centre 
survey designed to enumerate the proportion of patients 
developing pelvic tumour recurrence following contempo-
rary cystectomy.
Methods 
In 2011, 17 university-affiliated cancer clinics across Canada 
were invited to participate in this effort. Specifically, each 
centre was asked to identify a trio of investigators comprised 
of a pathologist, urologist, and radiation oncologist. Following 
ethics approval, the pathologist generated a chronologically 
accurate list of consecutive patients undergoing cystectomy 
for bladder cancer starting January 1, 2005. To be eligible 
for the study, the following criteria had to be met: 1) primary 
urothelial carcinoma with or without any admixed other 
histologies (no other primary histologies such as squamous, 
adenocarcinoma, or small cell were included); 2) no known 
hematogenous metastases or nodal involvement above the 
iliac bifurcation; 3) surgery performed with curative intent 
and no gross residual disease; 4) neoadjuvant or adjuvant 
chemotherapy was permitted; 5) only pT3/T4 N0-2 stages. 
The first 10 consecutive cases meeting these criteria, regard-
less of whether the subsequent clinical outcome was fully 
known or not, constituted the required patient sample from 
each institution. It was the expectation that this method 
of case selection from each hospital’s surgical pathology 
chronological record would minimize case selection bias. 
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Abstracted clinical data included birthdate, date of radical 
cystectomy, pathological stage, number of removed lymph 
nodes recorded in the pathology report, date of last clinical 
contact, and last known clinical status. Defining any hema-
togenous spread or nodal disease above or at L5 as distant 
metastases (DM) and any pelvic soft tissue or nodal disease 
below L5 as pelvic recurrence (PR), the eventual clinical 
status was categorized as: 1) no tumour recurrence; 2) pelvic 
recurrence only (with date); 3) distant metastases only (with 
date); 4) distant metastases and pelvic recurrence regardless 
of whether identified simultaneously or not; and 5) pelvic 
tumour status unknown. The anonymized individual patient 
data sheets were collated centrally for compilation and anal-
ysis. Arithmetic proportions of patients developing pelvic 
recurrence with or without distant metastases were tabulated 
and cumulative incidence calculations were performed to 
compute the risk of developing pelvic relapse.
Results 
Eleven university-affiliated cancer clinics (Vancouver, 
Edmonton, London, Kingston, Ottawa, Princess Margaret, 
Sunnybrook, McGill, CHUM, Saint John, and Sudbury) from 
five provinces participated.
Ten centres from five provinces provided data on 111 
patients (Table 1). Age ranged from 43.9–92.7 years, (mean/
median 69.6/70.9 years). T stage was pT3 in 81 patients 
(pT3a=39, pT3b=41, pT3NOS=1) and pT4 in 30 (pT4a=27, 
pT4b=2, pT4NOS=1). N stage was N0 in 62 patients, N1 in 
14, N2 in 27, and Nx in 8. The median number of nodes dis-
sected was 11 and ranged from 0–67. With regard to nodes, 
26.6% had more than 15 nodes resected; 21.1% had 11–15 
resected; 26.6% had 6–10 resected; 22.9% had 5 or less 
resected. Median time to last followup was 15 months, and 
ranged from 0–87 months. PR occurred in 34.2% of patients; 
51.4% had no PR. Pelvic status was unknown in 14.4%, but 
these were considered as having no PR. Of the 38 patients 
with PR, 25 (65.8%) developed DM and 13 (34.2%) had 
only PR. Fig. 1 shows the 40% pelvic recurrence rate when 
calculated as cumulative incidence. 
Discussion
Starting with Whitmores’ emphasis on the nodal dissection 
component of a radical cystectomy in 19624 to examina-
tion of planned perioperative adjuvant radiotherapy in the 
70s and 80s, Skinners’ compilation of the large, single-
institutional testament to comprehensive, meticulous surgi-
cal technique through the 90s,5 and calibrated further by 
Herrs’ elucidation of the importance of resected node counts 
in 2003,6 these strategies have addressed the all-important 
matter of pelvic tumour eradication in bladder cancer. In a 
2007 comprehensive review, Cagiannos et al tabulated con-
temporary post-cystectomy pelvic recurrence rates ranging 
from 3.9‒29%.7 These numbers have significantly underes-
timated the actual occurrence of loco-regional failures due 
to: 1) dilution by reporting overall rather than per T stage 
recurrence rates; 2) calculation of simple proportions rather 
than cumulative incidence risk; 3) requirement of biopsy 
confirmation; 4) discounting pelvic failure if accompanied 
or preceded by systemic metastases; and 5) relative inatten-
tion to pelvic imaging following the development of distant 
disease. These detriments to accurate risk determination are 
compounded by the known insensitivity of pelvic imaging 
in the context of subcentimetric tumour deposits.
 Two experiences published in 2005 and 2012 define 
the scope of this ongoing pelvic control issue. The SWOG 
trial of neoadjuvant chemotherapy featured a 32% biopsy-
proven crude simple pelvic relapse rate in T3/T4 patients.8 
The MRC trialists’ report of the long-term results of the 
seminal European neoadjuvant chemotherapy trial yield-
ed a 49% loco-regional relapse rate.9 While documenting 
the high intrapelvic recurrence rates, both these trials also 
demonstrate that although overall survival is improved by 
5%, neoadjuvant chemotherapy does not have a discernible 
impact on pelvic tumour control.
The 40% pelvic relapse rate in this cross-Canada 
study is in concert with the experiences detailed above. 
Unfortunately, it is likely that even this high risk is an under-
estimate, given that we used the conservative assumption 
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that patients in whom pelvic tumour status was unknown 
were free of tumour. 
The strength of our data is two-fold. Firstly, the data is 
a random snapshot of outcomes. By virtue of the patient 
retrieval strategy used, the selection biases that can occur 
when measuring outcomes in patients selected for partici-
pation in a clinical trial or abstracting data from cultivated 
institutional patient data sets is reduced. Secondly, and likely 
most importantly, the sole and simple object of this exer-
cise was to enumerate pelvic relapse in unselected patients 
undergoing contemporary surgery at widely dispersed aca-
demic institutions. This is in contrast to the general literature, 
wherein pelvic control is not the prime focus of published 
reports. 
Weaknesses of this data set are the relatively small num-
ber of cases audited at each centre (10), the limited rigour 
in determining pelvic tumour status in those patients for 
whom it was deemed “unknown” from the readily available 
documentation, and omission of surgical margin status. The 
latter two are a reflection of the practicalities of a multicentre 
survey.
Whereas enumeration defines the magnitude of the 
problem, understanding causation requires unraveling the 
interplay between the culprit clinical, surgical, and patho-
logical factors. In this Canadian patient cohort, node posi-
tivity predicted for higher PR (Fig. 2), while the number of 
lymph nodes resected appeared to not materially influence 
Fig. 3. Cumulative incidence of pelvic recurrence following cystectomy of 110 
patients; subgroups defined by number of nodes removed.
Month 0 12 24 36
At	risk	(events) 110	(25) 46	(10) 27	(3) 19	(0)
Fig. 2. Cumulative incidence of pelvic recurrence following cystectomy of 110 
patients; subgroups defined by nodal status at time of surgery.
Fig. 4. Cumulative incidence of pelvic recurrence following cystectomy of 110 
patients; subgroups defined by pathological tumour stage.
Fig. 1. Cumulative incidence of pelvic recurrence following cystectomy of 110 
patients; number of patients at risk and events occurring per 12-month period 
at bottom of graph.
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PR (Figs. 3 and 4). This latter observation is at odds with 
what currently comprises a cardinal aspect of radical cyst-
ectomy, whereby still more extensive nodal clearance is 
being advocated and investigated.10,11 Lymph node counts, 
be they absolute or proportional, are vulnerable to varia-
tions in retrieval from the resected specimen. Additionally, 
the relatively small number of patients and the possibility 
that patients with node-positive disease are more likely to 
manifest metastatic disease, thus reducing the clinical prob-
ability of identifying PR, likely explain this anomalous result. 
Our data must not be misconstrued as minimizing the 
importance of adequate nodal dissection. Christodouleas 
has validated, extramurally, the robustness of assigning 
post-cystectomy patients to low-, intermediate- and high-
risk categories on the basis of pathological stage, numbers 
of resected lymph nodes, and margin status.12 The soundness 
of this model has been further corroborated by Froehner13 
and Ku14 This stratification of PR risk accounts for tumour-
related parameters. Other factors can be considered as being 
patient- or treatment-related. Given that, by definition, all 
patients undergoing curative radical cystectomy had to be 
sufficiently well-suited in terms of medical condition and 
performance status to undergo the surgery, it is unlikely that 
other patient variables have contributed to the probability 
of PR. Treatment factors include the use of neo or adjuvant 
chemotherapy, thoroughness of the operation, and case vol-
ume issues that speak to the surgical team’s experience. As 
noted previously, randomized trial data show that adminis-
tering chemotherapy to these patients does not reduce PR 
rates. While nodal status is unequivocally a tumour par-
ameter, resected nodal counts definitely and margin status 
possibly also reflect surgical rigor. That all these patients 
underwent surgery at academic hospitals with cancer clinic 
affiliations speaks to the likely sufficient patient volumes and 
requisite surgical expertise. 
In the final analysis, this high rate of PR cannot be attrib-
uted to any unfortunate case mix or singular compromise 
of accepted bounds of contemporary surgical management. 
Rather, it is almost certainly a reflection of the true rates of 
pelvic failure revealed when the singular focus of the study 
is the number of pelvic relapses.
The approach of discounting pelvic recurrence if it 
coincides with or succeeds distant metastases speaks to a 
perspective that relegates loco-regional failure to the status 
of being an unfortunate, but clinically unimportant event. 
This derives from the fact that the majority of patients with 
pelvic relapse also develop distant disease. However, it 
remains the clinical reality that: 1) essentially, no patient 
with pelvic failure can be salvaged, rendering the magnitude 
of the pelvic relapse problem an absolute ceiling on surgical 
curability;  2) in the 15% minority of patients who develop 
isolated pelvic relapse, the clinical outcome is determined 
by local and not distant disease; and 3) patients with recur-
rent tumour in the pelvis can and do experience significant 
morbidity that is poorly palliated, whether or not distant 
disease coexists.
This study was undertaken because of the clinical percep-
tion that PR remains a significant problem following curative 
surgery in pT3/T4 urothelial bladder cancer, an issue that is 
not readily discernible in the uro-oncological  literature. The 
multi-institutional data presented corroborates this mater-
ially high risk of loco-regional failure following contempor-
ary radical cystectomy in advanced-stage presentation and 
emphasizes the need to address the issue definitively. Pelvic 
control is a necessary, but insufficient requirement for cure. 
Giving it the focus it warrants will enable uro-oncologists to 
elucidate the optimal, nuanced amalgam of surgery, radio-
therapy, and systemic therapies that maximizes the cure 
potential for the individual bladder cancer patient. 
In North America, the NRG clinical trials group15 has 
opened a randomized trial examining adjuvant radiother-
apy and similar studies are being launched in France, Asia, 
and the U.K. This is the currency of clinical investigation 
into the treatment of all other solid malignancies that has 
yielded ever-improving local, regional, and systemic control, 
a scenario that can be realistically anticipated for bladder 
cancer as well. 
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